Business - Briefly   

Orchid gets USFDA approval for Cefprozil

CHENNAI: The Chennai-based pharma major, Orchid Chemicals announced on Tuesday that it has received the formal approval from the USFDA for its ANDA (abbreviated new drug application) for Cefprozil for Oral Suspension USP, 125 mg/5 ml and 250 mg/5 ml. Cefprozil is the generic version of Bristol-Myers Squibb's broad-spectrum cephalosporin antibiotic Cefzil. The current U.S. market size for Cefprozil oral suspension is $120 million. Orchid is launching the product in the U.S. exclusively through its marketing alliance partner, Par Pharmaceuticals.

Printer friendly page  
Send this article to Friends by E-Mail

Stories in this Section

Sensex hits 9500-mark
CII favours cut in peak customs duty
SAFTA will enhance regional trade
Air-India awaiting advisor's report to finalise IPO plans
Increase tax-GDP ratio to 15 p. c. : Assocham
MPEDA to grant logo for quality
GEH staff get payments
Indian Bank's pilot project in Pondicherry
Tesco HSC to ramp up headcount
Rupee bounces back against dollar
Bullion rates
Exchange rates
ECB access for multi-State coops.
Tea Board appoints IIM(C)
Tata Motors officials meet WB CM
UTI Mutual Fund to launch new fund
BSE broker suspended
Covansys launches concept centre
Hummingbird partners HCL Tech
Chola MS launches Jeweller's Block
Three banks launch `no-frills' account
Bajaj Capital opens branch in Mangalore
Greek bank selects i-flex solution
Orchid gets USFDA approval for Cefprozil
New MD for BHPV, Visakhapatnam

Copyright © 2006, The Hindu. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu